# LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

> **NCT02058706** · PHASE2 · COMPLETED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 71 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** enzalutamide
- **DRUG:** bicalutamide
- **PROCEDURE:** orchiectomy
- **DRUG:** leuprolide acetate
- **DRUG:** goserelin acetate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02058706
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2021-03-01
- **Final completion:** 2021-03-01
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2023-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02058706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02058706, "LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02058706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*